Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ascidian Therapeutics
Biotech
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B
Ascidian and Lilly signed a collaboration worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases.
Will Maddox
Jun 3, 2026 7:00am
Apple Tree Partners files for Chapter 11 bankruptcy
Dec 10, 2025 4:54pm
Incyte, FDA, Sun Pharma and more—Chutes & Ladders
Jun 27, 2025 8:30am
CRISPR-focused Caribou christens new CMO—Chutes & Ladders
Aug 16, 2024 8:30am
Introducing Fierce Biotech's 2024 Fierce 15
Aug 5, 2024 6:00am
Roche pays Ascidian $42M to develop RNA exon editing drugs
Jun 18, 2024 7:00am
